NM_130839.5(UBE3A):c.1402del (p.Thr468fs)

For UBE3A c.1402del (p.Thr468fs), a pathogenic frameshift variant that ablates ubiquitin ligase function from the maternal allele, antisense oligonucleotide-mediated unsilencing of the intact paternal UBE3A allele in neurons is the most rational and clinically advanced therapeutic strategy. Three ASO programs targeting the UBE3A-ATS antisense transcript are in late-stage clinical development: ION582 (Ionis, Phase 3 REVEAL trial initiated, FDA Breakthrough Therapy designation), GTX-102/apazunersen (Ultragenyx, Phase 3 ASPIRE enrollment complete July 2025, topline data expected H2 2026), and rugonersen (Oak Hill Bio, Phase 1 TANGELO results published in Nature Medicine 2025). This approach is genotype-agnostic with respect to the maternal allele defect — it works by restoring expression from the structurally intact paternal UBE3A copy.

ION582 HALOS Phase 1/2 data (n=51, ages 2-50): 97% of medium- and high-dose patients showed improvement in overall AS symptoms after 3 doses over 6 months, with improvements in cognition, communication, and motor function exceeding natural history controls. Rugonersen TANGELO Phase 1 (n=61, ages 1-12, Nature Medicine 2025, PMID: 40646322): dose-dependent partial normalization of pathological EEG delta power and improvements on multiple exploratory endpoints. GTX-102 Phase 1/2: rapid clinically meaningful improvements in cognition and communication. Preclinical work by Meng et al. (2021, PMID: 34369389) demonstrated that ASO-mediated UBE3A-ATS knockdown rescued UBE3A expression and multiple phenotypes in AS mice. The critical period studies by Silva-Santos et al. (2015, PMID: 25866966) showed that motor deficits can be rescued by adolescent UBE3A reinstatement, while anxiety and epilepsy require early developmental intervention.

All three ASO programs require repeated intrathecal administration (lumbar puncture every few months), which is invasive particularly for pediatric patients. The developmental window is a central concern: some AS phenotypes (epilepsy, anxiety) may only be rescuable if treatment begins early in development. The Phase 3 ASPIRE trial for GTX-102 enrolls only deletion genotype patients ages 4-17; patients with point mutations or frameshift variants like c.1402del must wait for the AURORA study or ION582 REVEAL trial. Early GTX-102 dosing raised concerns about lower extremity weakness at higher doses, leading to protocol modifications. Seizure exacerbation has been reported as a treatment-related serious adverse event with rugonersen. ASO durability is limited — treatment cessation would presumably lead to re-silencing of paternal UBE3A over weeks to months.